Final Program

48 SUNDAY • MAY 15
P14
P15
P16
P17
P18
Facilitator:
P19
P20
P21
P22
P23
P24
P25
Anti-IgE Monoclonal Antibody Therapy as an Alternative for
the Treatment of Occupational Asthma Caused by Exposure to
Low Molecular Weight Agents/M.-J. Cruz, M. Olle-Monge, J.
Yllera-Retegui, M.-D. Untoria-Corral, D. Alvarez-Simon, X. Munoz,
Barcelona, Spain, p.A1309
Predictors of Inhaled Corticosteroid Reduction Failure in Adult
Asthmatics/J.C. Cardet, T.S. King, L.B. Bacharier, T.F. Carr, V.M.
Chinchilli, C.D. Codispoti, R.M. Dunn, F. Holguin, K.F. Nelson, V.E.
Ortega, M. Peters, S. Ramratnam, M.E. Wechsler, E. Israel,
Boston, MA, p.A1310
Knowledge of Risks of Asthma and Its Treatments Amongst
Healthcare Professionals: A Questionnaire-Based Survey/A.
Rameh, J. Blakey, Liverpool, United Kingdom, p.A1311
Serum Periostin Level May Predict Asthma Exacerbation After
Stepping Down Formoterol/Budesonide Combination Therapy
in Adult Asthma/H. Nagase, T. Shirai, T. Kawayama, H. Inoue, S.
Sato, K. Asano, K. Izuhara, H. Kume, Tokyo, Japan, p.A1312
Characteristic Features of Late-Onset Hypereosinophilic Asthma/
M. Toyoshima, Y. Kamiya, T. Suda, Hamamatsu, Japan, p.A1313
N. Miyahara, MD, PhD, Okayama, Japan
IL-13 Decreases M3R Expression in the Human Airway,
Reducing the Effect of Tiotropium on Mucin Production/K.
Komiya, S. Kawano, I. Suzaki, T. Akaba, J.L. Bradley, B.K. Rubin,
Richmond, VA, p.A1314
Mechanism of Reduced Glucocorticoid Sensitivity in Human
Pulmonary Epithelial Cells: Implications for Regulation by
Interferon Regulatory Factor (IRF1)/S.V. Shah, R. Newton,
Calgary, Canada, p.A1315
STRETTO: Design and Baseline Characteristics of a Phase III,
Double-Blind, Placebo-Controlled Study to Assess the Efficacy
and Safety of Lebrikizumab in Adult Patients with
Mild-to-Moderate Asthma/K. Yen, C.T.J. Holweg, J.
Anzures-Cabrera, C. Martin, J. Olsson, J.G. Matthews, South San
Francisco, CA, p.A1316
Clinical Symptom Burden in Severe Asthma One Year After
Completion of Bronchial Thermoplasty/M. Curtiss, Y. Wang, D.
Zhi, F. Wang, J.T. Anderson, M.T. Dransfield, J.S. Deshane, J.
Trevor, Birmingham, AL, p.A1317
LAVOLTA I and II: Design and Baseline Characteristics of Two
Phase III, Randomized, Double-Blind, Placebo-Controlled
Studies to Assess the Efficacy and Safety of Lebrikizumab in
Adult Patients with Uncontrolled Asthma/N.A. Hanania, P.
Korenblat, K.R. Chapman, E.D. Bateman, P. Kopecky, P. Paggiaro,
A. Yokoyama, J. Olsson, S. Gray, C.T.J. Holweg, M. Eisner, J.G.
Matthews, Houston, TX, p.A1318
Topical NSAID and NERD Phenotype Asthma Control/A.A. Hsu,
Singapore, Singapore, p.A1319
Clinical Endpoint Bioequivalence Study of Salmeterol
Xinafoate (SX)/Fluticasone Propionate (FP) Combination Brand
and Generic Candidate Products in Patients with Asthma/M.
Longphre, K. Beasley, E. Burmeister Getz, R. Fuller, Berkeley, CA,
p.A1320
P26
Facilitator:
P27
P28
P29
P30
P31
P32
P33
P34
P35
P36
P37
Plasma Inhaled Fluticasone Levels and Their Clinical
Implications in Asthma/A. Matsubara, A. Takahashi, E.
Yamaguchi, N. Yokoe, I. Okajima, K. Kosaka, M. Nishimura, H.
Tanaka, N. Asai, A. Kubo, Nagakute, Japan, p.A1321
J.G. Zangrilli, MD, Philadelphia, PA
Step Down Strategy; Can LTRA Be Withdrawn Safely From
Combination Therapy with Medium to High Dose of ICS/LABA,
Tiotropium Bromide and LTRA in Severe Asthmatics?/M. Hojo,
M. Iikura, M. Suzuki, H. Sugiyama, Tokyo, Japan, p.A1322
Safety and Efficacy of Vilanterol and Fluticasone
furoate/Vilanterol in the Treatment of Asthma: A Systematic
Review and Meta-Analysis/H. Zhou, C. Liu, Chengdu, China,
p.A1323
Extraction of Membrane Cholesterol as a Potential New
Therapeutic Mechanism in Asthma/G. Dufour, N. Rocks, A.
Duyckaerts, C. Gerard, M.-P. Mingeot-Leclercq, B. Evrard, D.
Cataldo, Liege, Belgium, p.A1324
Chinese Herbs for Acute Asthma: A Multi-Center, Randomized,
Double-Blind, Placebo-Controlled Trial/G. Wang, Chengdu,
China, p.A1325
Safety and Tolerability of AZD1419, an Inhaled
Oligonucleotide-Based Toll-Like Receptor 9 Agonist in Healthy
Volunteers: A Potential New Therapy for Asthma/S. Jackson, S.
Floettmann, A. Candia, C. Wong, S. Delaney, D. Keeling, R. Fuhr,
R.L. Coffman, Berkeley, CA, p.A1326
Efficacy of the Anti-IgE Monoclonal Antibody Omalizumab in
Patients with Severe Asthma Complicated with Eosinophilic
Otitis Media/E. Tagaya, R. Mizobuchi, A. Kubo, K. Hara, K.
Takeyama, M. Kondo, J. Tamaoki, Tokyo, Japan, p.A1327
Interleukin 17 (IL-17) Targeting Therapy in Asthma/M.
Mahdavian, A. Ferrell, S. Asghari, Y. Yi, S.D. Aaron, Ottawa,
Canada, p.A1328
A Novel Inhaled Non-Steroidal Modulator of Inflammation for
the Control of Asthma; AZD7594/C.K. Mardh, W. Russell, M.
Gustavsson, N. Kurian, A.-H. Jansson, A. Smailagic, K. Edman,
Molndal, Sweden, p.A1329
Assessment of Asthma Control in Adults Using Extrafine
Inhaled Beclomethasone/Formoterol Combination as
Maintenance Therapy or Maintenance and Reliever Therapy: A
Multicentre Prospective Observational Study/R. Pawliczak, B.
Rogala, T. Debowski, Lodz, Poland, p.A7769
RPL554, a First-In-Class Dual Phosphodiesterase (PDE)3/4
Inhibitor, Is Equi-Effective as a Bronchodilator to Maximal
Doses of Salbutamol in Asthmatics but with Fewer Adverse
Events/L. Bjermer, J. Stewart, K.H. Abbott-Banner, K. Newman,
Lund, Sweden, p.A7770
A Potential Mechanism for Steroid Resistance in Severe
Asthma/M. Gauthier, T. Oriss, M. Raundhal, C. Morse, S.E.
Wenzel, P. Ray, A. Ray, Pittsburgh, PA, p.A7771
ATS 2016 • San Francisco